Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer

J Natl Cancer Inst. 2012 Oct 3;104(19):1518-23. doi: 10.1093/jnci/djs376.
No abstract available

Publication types

  • Published Erratum

MeSH terms

  • Administration, Oral
  • Aged
  • Aged, 80 and over
  • Androgen Antagonists / administration & dosage
  • Androgen Antagonists / adverse effects*
  • Antineoplastic Agents, Hormonal / administration & dosage
  • Antineoplastic Agents, Hormonal / adverse effects*
  • Cardiovascular Diseases / chemically induced*
  • Cardiovascular Diseases / epidemiology*
  • Cardiovascular Diseases / etiology
  • Coronary Disease / chemically induced
  • Coronary Disease / epidemiology
  • Death, Sudden, Cardiac / epidemiology
  • Death, Sudden, Cardiac / etiology
  • Diabetes Mellitus, Type 2 / chemically induced
  • Diabetes Mellitus, Type 2 / epidemiology
  • Gonadotropin-Releasing Hormone / agonists
  • Humans
  • Incidence
  • Male
  • Middle Aged
  • Myocardial Infarction / chemically induced
  • Myocardial Infarction / epidemiology
  • Odds Ratio
  • Orchiectomy / adverse effects
  • Proportional Hazards Models
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology*
  • Stroke / chemically induced
  • Stroke / epidemiology
  • United States / epidemiology
  • Veterans / statistics & numerical data*

Substances

  • Androgen Antagonists
  • Antineoplastic Agents, Hormonal
  • Gonadotropin-Releasing Hormone